Advertisement
Table 1 Comparison of clinical and molecular characteristics with miR-425 expression in AML patients
| Characteristic | Chemotherapy group | Allo-HSCT group | ||||
|---|---|---|---|---|---|---|
| High miR-425 (n = 45) | Low miR-425 (n = 45) | P | High miR-425 (n = 36) | Low miR-425 (n = 36) | P | |
| Age/years, median (range) | 63 (22–88) | 68 (33–83) | 0.138 | 52 (25–72) | 50 (18–69) | 0.450 |
| Age group/no. (%), years | 0.652 | 0.793 | ||||
| < 60 | 16 (35.6) | 13 (28.9) | 27 (75.0) | 25 (69.4) | ||
| ≥ 60 | 29 (64.4) | 32 (71.1) | 9 (25.0) | 11 (30.6) | ||
| Gender/no. (%) | 0.289 | 1.000 | ||||
| Male | 28 (62.2) | 22 (48.9) | 21 (58.3) | 20 (55.6) | ||
| Female | 17 (37.8) | 23 (51.1) | 15 (41.7) | 16 (44.4) | ||
| WBC/× 109/L, median (range) | 15.2 (0.7–298.4) | 16.9 (1.0–297.4) | 0.589 | 30.3 (1.5–98.8) | 28.3 (0.6–223.8) | 0.978 |
| BM blast/ %, median (range) | 67 (30–98) | 75 (37–99) | 0.050 | 68 (30–97) | 76 (35–100) | 0.131 |
| PB blast/%, median (range) | 18 (0–71) | 53 (0–98) | 0.002 | 41 (0–85) | 53 (0–96) | 0.116 |
| FAB subtypes/no. (%) | ||||||
| M0 | 0 (0.0) | 8 (17.8) | 0.006 | 3 (8.3) | 6 (16.7) | 0.478 |
| M1 | 7 (15.6) | 13 (28.9) | 0.201 | 8 (22.2) | 15 (41.7) | 0.129 |
| M2 | 13 (28.9) | 8 (17.8) | 0.231 | 13 (36.1) | 6 (16.7) | 0.107 |
| M4 | 14 (31.1) | 10 (22.2) | 0.340 | 8 (22.2) | 6 (16.7) | 0.767 |
| M5 | 9 (20) | 4 (8.9) | 0.230 | 3 (8.3) | 1 (2.8) | 0.614 |
| M6 | 0 (0.0) | 1 (2.2) | 1.000 | 1 (2.8) | 0 (0.0) | 1.000 |
| M7 | 1 (2.2) | 1 (2.2) | 1.000 | 0 (0.0) | 1 (2.8) | 1.000 |
| Others | 1 (2.2) | 0 (0.0) | 1.000 | 0 (0.0) | 1 (2.8) | 1.000 |
| Karyotype/no. (%) | ||||||
| Normal | 21 (46.7) | 23 (51.1) | 0.833 | 17 (47.2) | 17 (47.2) | 1.000 |
| Complex | 5 (11.1) | 7 (15.6) | 0.758 | 5 (13.9) | 7 (19.4) | 0.753 |
| MLL rearranged | 2 (4.4) | 1 (2.2) | 1.000 | 2 (5.6) | 1 (2.8) | 1.000 |
| CBFβ-MYH11 | 7 (15.6) | 0 (0.0) | 0.012 | 5 (13.9) | 0 (0.0) | 0.054 |
| BCR-ABL1 | 1 (2.2) | 0 (0.0) | 1.000 | 1 (2.8) | 1 (2.8) | 1.000 |
| RUNX1-RUNX1T | 5 (11.1) | 1 (2.2) | 0.203 | 0 (0.0) | 1 (2.8) | 1.000 |
| Others | 4 (8.9) | 13 (28.9) | 0.029 | 6 (16.7) | 9 (25) | 0.563 |
| Risk (cyto)/no. (%) | ||||||
| Good | 12 (26.7) | 1 (2.2) | 0.002 | 5 (13.9) | 1 (2.8) | 0.199 |
| Intermediate | 20 (44.4) | 30 (66.7) | 0.056 | 17 (47.2) | 24 (66.7) | 0.153 |
| Poor | 13 (28.9) | 12 (26.7) | 1.000 | 13 (36.1) | 11 (30.6) | 0.803 |
| Others | 0 (0.0) | 2 (4.4) | 0.494 | 1 (2.8) | 0 (0.0) | 1.000 |
| FLT3-ITD/no. (%) | 1.000 | 0.396 | ||||
| Presence | 8 (17.8) | 8 (17.8) | 6 (16.7) | 10 (27.8) | ||
| Absence | 37 (82.2) | 37 (82.2) | 30 (83.3) | 26 (72.2) | ||
| NPM1/no. (%) | 0.367 | 0.430 | ||||
| Presence | 12 (26.7) | 17 (37.8) | 8 (22.2) | 12 (33.3) | ||
| Absence | 33 (73.3) | 28 (62.2) | 28 (77.8) | 24 (66.7) | ||
| DNMT3A/no. (%) | 0.059 | 0.415 | ||||
| Presence | 8 (17.8) | 17 (37.8) | 7 (19.4) | 11 (30.6) | ||
| Absence | 37 (82.2) | 28 (62.2) | 29 (80.6) | 25 (69.4) | ||
| RUNX1/no. (%) | 0.058 | 1.000 | ||||
| Presence | 1 (2.2) | 7 (15.6) | 4 (11.1) | 4 (11.1) | ||
| Absence | 44 (97.8) | 38 (84.4) | 32 (88.9) | 32 (88.9) | ||
| MLL-PTD/no. (%) | 1.000 | 0.115 | ||||
| Presence | 2 (4.4) | 3 (6.7) | 4 (11.1) | 0 (0.0) | ||
| Absence | 43 (95.6) | 42 (93.3) | 32 (88.9) | 36 (100.0) | ||
| TP53/no. (%) | 1.000 | 1.000 | ||||
| Mutation | 5 (11.1) | 5 (11.1) | 2 (5.6) | 2 (5.6) | ||
| Wild type | 40 (88.9) | 40 (88.9) | 34 (94.4) | 34 (94.4) | ||
| CEBPA/no. (%) | 1.000 | 1.000 | ||||
| Mutation | 2 (4.4) | 1 (2.2) | 4 (11.1) | 4 (11.1) | ||
| Wild type | 43 (95.6) | 44 (97.8) | 32 (89.9) | 32 (88.9) | ||
| IDH1/no. (%) | 0.012012 | 0.514 | ||||
| Mutation | 0 (0.0) | 7 (15.6) | 4 (11.1) | 7 (19.4) | ||
| Wild type | 45 (100.0) | 38 (84.4) | 32 (88.9) | 29 (80.6) | ||
| IDH2/no. (%) | 1.000 | 0.710 | ||||
| Mutation | 4 (8.9) | 5 (11.1) | 3 (8.3) | 5 (13.9) | ||
| Wild type | 41 (91.1) | 40 (88.9) | 33 (91.7) | 31 (86.1) | ||
